Altitude Sickness (Acute mountain sickness) – Pipeline Review, H1 2012

Altitude Sickness (Acute mountain sickness) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Altitude Sickness (Acute mountain sickness) - Pipeline Review, H1 2012', provides an overview of the Altitude Sickness (Acute mountain sickness) therapeutic pipeline. This report provides information on the therapeutic development for Altitude Sickness (Acute mountain sickness), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Altitude Sickness (Acute mountain sickness). 'Altitude Sickness (Acute mountain sickness) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Altitude Sickness (Acute mountain sickness).
• A review of the Altitude Sickness (Acute mountain sickness) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Altitude Sickness (Acute mountain sickness) pipeline on the basis of route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Altitude Sickness (Acute mountain sickness).
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Altitude Sickness (Acute mountain sickness) pipeline depth and focus of Altitude Sickness (Acute mountain sickness) therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Altitude Sickness (Acute mountain sickness) Overview
Therapeutics Development
An Overview of Pipeline Products for Altitude Sickness (Acute mountain sickness)
Altitude Sickness (Acute mountain sickness) Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Altitude Sickness (Acute mountain sickness) Therapeutics – Products under Investigation by Universities/Institutes
Altitude Sickness (Acute mountain sickness) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Acetazolamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
N-Acetylcysteine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
N-Acetylcysteine + Acetazolamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Altitude Sickness (Acute mountain sickness), H1 2012
Products under Development for Altitude Sickness (Acute mountain sickness) – Comparative Analysis, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012

LIST OF FIGURES

Number of Products under Development for Altitude Sickness (Acute mountain sickness), H1 2012
Products under Development for Altitude Sickness (Acute mountain sickness) – Comparative Analysis, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Mid Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012 Skip to top